Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
1.
Curr Med Chem ; 21(17): 1938-55, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24606495

ABSTRACT

The extensively investigated serine/threonine kinase, B-RAF, is a member of the RAS/RAF/MEK/ERK pathway. It plays important role in the regulation of cell growth, differentiation and survival. The mutation of B-RAF occurs frequently in melanomas and colon tumors; therefore, it is considered as an outstanding therapeutic target. In recent years a great number of B-RAF inhibitors have been reported and this number is expected to increase. The aim of our work was to compare the structures and binding mode of the published B-RAF inhibitors, and then to apply the correlations found for the explanation of our experimental results. In the first part of this paper we describe the main pharmacophore features of the co-crysallized B-RAF inhibitors published in the literature, focusing on the binding modes and common structural elements. In the second part we present and characterize our recently developed B-RAF inhibitor family by application of in silico methods and in vitro kinetic profiling. The inhibitory activity of these compounds was determined in biochemical kinase- and cell-based assays. The docking and assay results support our conclusion that the presented compound family belongs to the type I 1/2 subgroup, they inhibit B-RAF and B-RAF(V600E) mutant in a sub-micromolar range and most of them show selectivity towards B-RAF(V600E) mutant expressing cell lines with equal or even better IC50 values than sorafenib.


Subject(s)
Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Animals , Cell Line, Tumor , Humans , Molecular Docking Simulation , Mutation , Protein Binding , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism
2.
Cell Death Differ ; 14(6): 1117-28, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17363964

ABSTRACT

MCF-7 cells undergo autophagic death upon tamoxifen treatment. Plated on non-adhesive substratum these cells died by anoikis while inducing autophagy as revealed by monodansylcadaverine staining, elevated light-chain-3 expression and electron microscopy. Both de novo and anoikis-derived autophagic dying cells were engulfed by human macrophages and MCF-7 cells. Inhibition of autophagy by 3-methyladenine abolished engulfment of cells dying through de novo autophagy, but not those dying through anoikis. Blocking exposure of phosphatidylserine (PS) on both dying cell types inhibited phagocytosis by MCF-7 but not by macrophages. Gene expression profiling showed that though both types of phagocytes expressed full repertoire of the PS recognition and signaling pathway, macrophages could evolve during engulfment of de novo autophagic cells the potential of calreticulin-mediated processes as well. Our data suggest that cells dying through autophagy and those committing anoikis with autophagy may engage in overlapping but distinct sets of clearance mechanisms in professional and non-professional phagocytes.


Subject(s)
Autophagy/physiology , Macrophages/physiology , Phagocytes/physiology , Anoikis/drug effects , Anoikis/physiology , Autophagy/drug effects , Autophagy/genetics , Cell Death/drug effects , Cell Death/genetics , Cell Death/physiology , Cell Line, Tumor , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial Cells/ultrastructure , Humans , Immunoblotting , Macrophages/cytology , Macrophages/metabolism , Microscopy, Confocal , Microscopy, Electron, Transmission , Phagocytes/cytology , Phagocytes/metabolism , Phagocytosis/drug effects , Phosphatidylserines/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tamoxifen/pharmacology , Transcription, Genetic
4.
J Clin Pathol ; 58(7): 751-6, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15976346

ABSTRACT

BACKGROUND: Fibrosarcomatous (FS) or malignant fibrous histiocytomatous (MFH) transformation of dermatofibrosarcoma protuberans (DFSP) is a rare, but well known, entity. DFSPs with sarcomatous areas have questionable biological behaviour. Several studies suggest that they have a higher risk for local recurrence and distant metastases than ordinary DFSPs. One recent study described no difference in the behaviour of conventional and transformed DFSP. AIMS: To investigate the biological behaviour of a series of transformed DFSPs. METHODS: Eight transformed DFSPs were analysed clinicopathologically. Follow up ranged from four to 36 years. RESULTS: The tumours involved the trunk (six cases) and lower extremity (two cases) and measured 3.5-8 cm (median, 4). Sarcomatous change presented de novo in all cases. The type of sarcomatous change was FS (five cases) and MFH (three cases). The estimated proportion of sarcomatous area in the tumour was 25-70% (median, 43.37%). Mitotic counts ranged from nine to 16 mitotic figures/10 high power fields in the FS and MFH areas (median, 12), and from one to three in the DFSP areas. Six patients were treated by wide local excision with histopathologically negative margins and two were treated by simple surgical excision with positive margins. Three patients developed recurrences and one developed metastasis during follow up. Of those treated by wide local excision, one developed recurrence. All tumours expressed CD34 in the DFSP component, but only three in the sarcomatous area. CONCLUSIONS: Although DFSP containing sarcoma may be a more aggressive tumour, its behaviour can be influenced by surgical treatment.


Subject(s)
Dermatofibrosarcoma/pathology , Skin Neoplasms/pathology , Adult , Dermatofibrosarcoma/surgery , Disease Progression , Female , Fibrosarcoma/pathology , Fibrosarcoma/surgery , Follow-Up Studies , Histiocytoma, Benign Fibrous/pathology , Histiocytoma, Benign Fibrous/secondary , Histiocytoma, Benign Fibrous/surgery , Humans , Male , Middle Aged , Mitosis , Neoplasm Recurrence, Local , Prognosis , Skin Neoplasms/surgery
5.
Fogorv Sz ; 94(4): 145-50, 2001 Aug.
Article in Hungarian | MEDLINE | ID: mdl-11573456

ABSTRACT

The purpose of this review was to give a complete summary of the ADHD (Attention Deficit Hyperactivity Disorder) for dentists, especially for those who deal with dental traumatology. Children with ADH disorder show symptoms of restlessness, hyperactivity, impulsive behaviour and inattention often resulting in serious dental accidents. The article summarizes the literary data concerning ADH-Syndrome, presents a typical case and also deals with the dental considerations.


Subject(s)
Attention Deficit Disorder with Hyperactivity , Dental Care for Children/methods , Pediatric Dentistry/methods , Child , Humans
6.
J Struct Biol ; 135(1): 73-7, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11562168

ABSTRACT

Transglutaminases(TGases; protein-glutamine-glutamyl-transferases) are a large family of calcium-dependent acyl-transfer enzymes that catalyze the formation of covalent cross links in proteins. Of these, the "epidermal" or "hair follicle" TGase 3 isoform is critically involved in barrier formation in epithelia. It is a zymogen, requiring proteolytic activation to achieve maximal specific activity. In order to understand its structure and function, we have devised methods for the rapid large-scale expression of the TGase 3 zymogen in the baculovirus system, and here we describe the purification of the zymogen and activated forms. We describe methods for the formation of high-quality, well-diffracting crystals within 3-5 days, using both dioxane and beta-octylglucoside to overcome severe twinning problems. The crystal of the zymogen belongs to the triclinic space group P1 and diffracts to 2.2-A resolution, and the crystal of the active form belongs to the P2(1) space group at 2.7-A resolution.


Subject(s)
Calcium-Binding Proteins/chemistry , Enzyme Precursors/isolation & purification , Recombinant Proteins/chemistry , Spodoptera/virology , Transglutaminases/chemistry , Animals , Baculoviridae/genetics , Base Sequence , Cryoprotective Agents/metabolism , Crystallization , Crystallography, X-Ray/methods , DNA, Viral/genetics , Enzyme Activation , Genetic Vectors , Humans , Liposomes , Molecular Weight , Plasmids , Promoter Regions, Genetic , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Spodoptera/cytology , Time Factors , Transfection
8.
Neurobiol Aging ; 22(3): 403-6, 2001.
Article in English | MEDLINE | ID: mdl-11378245

ABSTRACT

N(epsilon)(gamma-glutamyl)lysine isodipeptide is released from the breakdown of proteins cross-linked by transglutaminase enzymes. Transglutaminase activation is a marker of apoptosis and elevated isodipeptide concentrations in body fluids might correlate with the intensity of apoptotic cell turnover. The concentration of N(epsilon)(gamma-glutamyl)lysine was measured in the cerebrospinal fluid (CSF) of patients with probable Alzheimer's disease (n = 14) and vascular type dementia (n = 11) and compared with not demented surgical controls (n = 17). Baseline levels of 26-62 nM/l (mean 37.9 +/- 8.7 SD) free isodipeptide were detected in control patients. CSF isodipeptide levels showed significant elevation in vascular (mean 95.6 +/- 45.1 SD) as well as Alzheimer patients (176.6 +/- 77.1 SD). Isodipeptide concentrations above 120 nM/l were 72% specific and 77% sensitive to Alzheimer's dementia, although the difference between the two dementias was statistically insignificant (p > 0.05). Determination of CSF N(epsilon)(gamma-glutamyl)lysine isodipeptide concentration offers a novel method for measurement of neurodegeneration in primary and mixed dementias.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , Dementia, Vascular/cerebrospinal fluid , Dementia, Vascular/diagnosis , Dipeptides/cerebrospinal fluid , Aged , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Apoptosis , Dementia, Vascular/metabolism , Dementia, Vascular/pathology , Dipeptides/metabolism , Female , Humans , Linear Models , Male
9.
Orv Hetil ; 141(10): 499-502, 2000 Mar 05.
Article in Hungarian | MEDLINE | ID: mdl-10750403

ABSTRACT

The leptospirosis and the hantaviral infections are worldwide distributed zoonoses having the similar epidemiology and clinical symptoms. Both in Europe and Asia those hantaviral serotypes are common which are responsible for the haemorrhagic fever with renal syndrome, while on the American continent the hantaviral pulmonary syndrome has also been diagnosed. Authors describe a patient who had simultaneous leptospira and hantaviral infections with haemorrhagic fever as well as with mild, transient renal insufficiency and liver damage. The dual infection was proved by serology.


Subject(s)
Hantavirus Infections/complications , Hantavirus Infections/diagnosis , Leptospirosis/complications , Leptospirosis/diagnosis , Diagnosis, Differential , Hemorrhagic Fever with Renal Syndrome/complications , Hemorrhagic Fever with Renal Syndrome/diagnosis , Humans , Middle Aged
10.
J Biol Chem ; 275(4): 2636-46, 2000 Jan 28.
Article in English | MEDLINE | ID: mdl-10644724

ABSTRACT

The loss of transglutaminase 1 enzyme (TGase 1) activity causes lamellar ichthyosis. Recessive X-linked ichthyosis (XI) results from accumulation of excess cholesterol 3-sulfate (CSO(4)) in the epidermis but the pathomechanism how elevated epidermal CSO(4) causes ichthyosis is largely unknown. Here we provide evidence that XI is also a consequence of TGase 1 dysfunction. TGase 1 is a key component of barrier formation in keratinocytes: it participates in the cross-linking of cell envelope (CE) structural proteins, and also forms the lipid bound envelope by esterification of long chain omega-hydroxyceramides onto CE proteins. Using involucrin and an epidermal omega-hydroxyceramide analog as substrates, kinetic analyses revealed that at membrane concentrations above 4 mol %, CSO(4) caused a marked and dose-dependent inhibitory effect on isopeptide and ester bond formation. Sequencing of tryptic peptides from TGase 1-reacted involucrin showed a large increase in deamidation of substrate glutamines. We hypothesize that supraphysiological levels of CSO(4) in keratinocyte membranes distort the structure of TGase 1 and facilitate the access of water into its active site causing hydrolysis of substrate glutamine residues. Our findings provide further evidence for the pivotal role of the TGase 1 enzyme in CE formation.


Subject(s)
Cholesterol Esters/metabolism , Epidermis/metabolism , Transglutaminases/metabolism , Base Sequence , Chromatography, High Pressure Liquid , DNA Primers , Epidermis/enzymology , Esterification , Glycine/chemistry , Humans , Hydrolysis , Lysine/chemistry , Mutation , Protein Precursors/chemistry , Protein Precursors/genetics , Protein Precursors/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
11.
Cell Death Differ ; 7(12): 1225-33, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11175260

ABSTRACT

Tissue transglutaminase (tTG) is upregulated in various cells undergoing apoptosis. To investigate the transcriptional regulation of tTG a mouse strain carrying a beta-galactosidase reporter gene under the control of a 3.8 kilobase fragment of the tTG promoter was characterised. The transgene construct was shown to be expressed in the apoptotic regions of the mouse embryo. Here we report that the regulation of the transgene is also apoptosis-linked in adult animals. The transgene is induced in endocrine apoptosis involving mammary gland involution and corpus luteum regression. Induction of the reporter gene is detectable during in vivo but not in vitro apoptosis of thymocytes induced by the glucocorticoid receptor, the nur77, p53 and the retinoid receptor gamma mediated pathways. Additionally, the lacZ expression mimics the activation of the endogenous promoter in tissues characterised by high apoptotic turnover. These results suggest that the apoptosis-specific transcriptional regulation of tTG is mediated through elements of a 3.8 kb promoter and may require cosignals available only in tissue environment. Cell Death and Differentiation (2000) 7, 1225 - 1233.


Subject(s)
Apoptosis/genetics , Promoter Regions, Genetic/physiology , Transglutaminases/genetics , Up-Regulation/genetics , Animals , Breast/cytology , Breast/metabolism , Cells, Cultured , Female , Gene Expression Regulation/physiology , Genes, Regulator/physiology , Genes, Reporter/physiology , Mice , Mice, Transgenic/metabolism , Ovary/cytology , Ovary/metabolism , RNA, Messenger/metabolism , Thymus Gland/cytology , Thymus Gland/metabolism , Transgenes/physiology , beta-Galactosidase/genetics
12.
Proc Natl Acad Sci U S A ; 96(15): 8402-7, 1999 Jul 20.
Article in English | MEDLINE | ID: mdl-10411887

ABSTRACT

Transglutaminases (TGases) are defined as enzymes capable of forming isopeptide bonds by transfer of an amine onto glutaminyl residues of a protein. Here we show that the membrane-bound form of the TGase 1 enzyme can also form ester bonds between specific glutaminyl residues of human involucrin and a synthetic analog of epidermal specific omega-hydroxyceramides. The formation of a approximately 5-nm-thick lipid envelope on the surface of epidermal keratinocytes is an important component of normal barrier function. The lipid envelope consists of omega-hydroxyceramides covalently linked by ester bonds to cornified envelope proteins, most abundantly to involucrin. We synthesized an analog of natural omega-hydroxyceramides N-[16-(16-hydroxyhexadecyl)oxypalmitoyl]sphingosine (lipid Z). When recombinant human TGase 1 and involucrin were reacted on the surface of synthetic lipid vesicles containing lipid Z, lipid Z was attached to involucrin and formed saponifiable protein-lipid adducts. By mass spectroscopy and sequencing of tryptic lipopeptides, the ester linkage formation used involucrin glutamine residues 107, 118, 122, 133, and 496 by converting the gamma-carboxamido groups to lipid esters. Several of these residues have been found previously to be attached to ceramides in vivo. Mass spectrometric analysis after acetonide derivatization also revealed that ester formation involved primarily the omega-hydroxyl group of lipid Z. Our data reveal a dual role for TGase 1 in epidermal barrier formation and provide insights into the pathophysiology of lamellar ichthyosis resulting from defects of TGase 1 enzyme.


Subject(s)
Ceramides/chemistry , Protein Precursors/chemistry , Transglutaminases/metabolism , Amino Acid Sequence , Enzyme Inhibitors/pharmacology , Epidermis/metabolism , Esterification , Glutamine/metabolism , Humans , Ichthyosis/metabolism , Mass Spectrometry , Molecular Sequence Data , Molecular Structure , Peptide Fragments/analysis , Putrescine/pharmacology , Recombinant Proteins/metabolism , Sequence Analysis , Substrate Specificity , Trypsin
13.
Orv Hetil ; 140(18): 987-91, 1999 May 02.
Article in Hungarian | MEDLINE | ID: mdl-10349322

ABSTRACT

Hairy cell leukaemia (HCL) is a rare, clinically and haematologically well characterised entity. The prognosis of patients with hairy cell leukaemia has significantly improved due to the new therapeutic approaches. Development of diagnostic and therapeutic methods, together with the analysis of their own hairy cell leukaemia patients, is reviewed by the authors. Between 1977 and 1998 twenty five patients (16 male, 9 female) were treated. The malignant cells were usually analysed by morphological and cytochemical methods and recently flow cytometric analysis could be performed in eight patients. Splenectomy with lethal outcome in six patients was performed in 21 cases. Approximately one third of patients received interferon, while 2-chlorodeoxyadenosine was given only to three patients. Favourable experiences obtained by splenectomy and efficacy of interferon treatment are emphasised, but according to the literature and their own results administration of purine analogues can be highly recommended in the future.


Subject(s)
Leukemia, Hairy Cell , Adult , Aged , Aged, 80 and over , Deoxyadenosines/therapeutic use , Female , Humans , Interferons/therapeutic use , Leukemia, Hairy Cell/drug therapy , Leukemia, Hairy Cell/pathology , Leukemia, Hairy Cell/surgery , Male , Middle Aged , Purines/therapeutic use , Splenectomy/adverse effects , Treatment Outcome
14.
Orv Hetil ; 140(19): 1059-61, 1999 May 09.
Article in Hungarian | MEDLINE | ID: mdl-10339998

ABSTRACT

Sweet's syndrome is an acute febrile neutrophilic dermatosis. Classical form occurs after infection of the gastrointestinal or respiratory tract. This syndrome is often associated with myeloproliferative disorders and solid tumors. Some cases are reported in the literature in which usage of granulocyte colony-stimulating factor induced the symptoms of Sweet's syndrome. We report the case of an 53-year-old woman with hyperthyreosis. She wasn't euthyreoid in spite of medicaments since 1994, so her doctors planned operation. In the preoperative period her peripheral blood revealed agranulcytosis and she has got fever. 2 days after administration of granulocyte colony-stimulating factor erythematous plaques appeared on her face, neck and extremities. Biopsy from these plaques showed dermal neutrophilia, so a diagnosis of neutrophilic dermatosis was made. After the administration of corticosteroids, immunglobulin and antibiotics the skin lesions were resolved. She was examined because of suspicion of autoimmune diseases but we couldn't find any of them. Retrospectively, appearance of Sweet's syndrome was associated with granulocyte colony-stimulating factor. The case of this woman is important because usage of colony-stimulating factors is widespread and the Sweet's syndrome could be occurs as side effect of these drugs.


Subject(s)
Granulocyte Colony-Stimulating Factor/adverse effects , Hyperthyroidism/drug therapy , Sweet Syndrome/chemically induced , Adrenal Cortex Hormones/therapeutic use , Female , Granulocyte Colony-Stimulating Factor/pharmacology , Humans , Middle Aged , Neutrophils/pathology , Skin/pathology , Sweet Syndrome/drug therapy , Sweet Syndrome/pathology
15.
Exp Mol Med ; 31(1): 5-19, 1999 Mar 31.
Article in English | MEDLINE | ID: mdl-10231017

ABSTRACT

A specialized tissue type, the keratinizing epithelium, protects terrestrial mammals from water loss and noxious physical, chemical and mechanical insults. This barrier between the body and the environment is constantly maintained by reproduction of inner living epidermal keratinocytes which undergo a process of terminal differentiation and then migrate to the surface as interlocking layers of dead stratum corneum cells. These cells provide the bulwark of mechanical and chemical protection, and together with their intercellular lipid surroundings, confer water-impermeability. Much of this barrier function is provided by the cornified cell envelope (CE), an extremely tough protein/lipid polymer structure formed just below the cytoplasmic membrane and subsequently resides on the exterior of the dead cornified cells. It consists of two parts: a protein envelope and a lipid envelope. The protein envelope is thought to contribute to the biomechanical properties of the CE as a result of cross-linking of specialized CE structural proteins by both disulfide bonds and N(epsilon)-(gamma-glutamyl)lysine isopeptide bonds formed by transglutaminases. Some of the structural proteins involved include involucrin, loricrin, small proline rich proteins, keratin intermediate filaments, elafin, cystatin A, and desmosomal proteins. The lipid envelope is located on the exterior of and covalently attached by ester bonds to the protein envelope and consists of a monomolecular layer of omega-hydroxyceramides. These not only serve of provide a Teflon-like coating to the cell, but also interdigitate with the intercellular lipid lamellae perhaps in a Velcro-like fashion. In fact the CE is a common feature of all stratified squamous epithelia, although its precise composition, structure and barrier function requirements vary widely between epithelia. Recent work has shown that a number of diseases which display defective epidermal barrier function, generically known as ichthyoses, are the result of genetic defects of the synthesis of either CE proteins, the transglutaminase 1 cross-linking enzyme, or defective metabolism of skin lipids.


Subject(s)
Epidermis/chemistry , Epidermis/metabolism , Keratinocytes/metabolism , Membrane Lipids/metabolism , Membrane Proteins/metabolism , Animals , Cell Membrane/metabolism , Humans , Ichthyosis/genetics , Ichthyosis/metabolism , Keratinocytes/chemistry , Transglutaminases/metabolism
16.
J Biol Chem ; 274(16): 11013-21, 1999 Apr 16.
Article in English | MEDLINE | ID: mdl-10196183

ABSTRACT

The transglutaminase 1 (TGase 1) enzyme is essential for the assembly of the cell envelope barrier in stratified squamous epithelia. It is usually bound to membranes, but to date most studies with it have involved solution assays. Here we describe an in vitro model system for characterizing the function of TGase 1 on the surface of synthetic lipid vesicles (SLV) of composition similar to eukaryote plasma membranes. Recombinant baculovirus-expressed human TGase 1 readily binds to SLV and becomes active in cross-linking above 10 microM Ca2+, in comparison to above 100 microM in solution assays, suggesting that the membrane surface is important for enzyme function. Involucrin also binds to SLV containing 12-18% phosphatidylserine and at Ca2+ concentrations above 1 microM. In reactions of involucrin with TGase 1 enzyme in solution, 80 of its 150 glutamines serve as donor residues. However, on SLV carrying both involucrin and TGase 1, only five glutamines serve as donors, of which glutamine 496 was the most favored. As controls, there was no change in specificity toward the glutamines of other substrates used by free or SLV-bound TGase 1 enzyme. We propose a model in which involucrin and TGase 1 bind to membranes shortly after expression in differentiating keratinocytes, but cross-linking begins only later as intracellular Ca2+ levels increase. Furthermore, the data suggest that the membrane surface regulates the steric interaction of TGase 1 with substrates such as involucrin to permit specific cross-linking for initiation of cell envelope barrier formation.


Subject(s)
Protein Precursors/metabolism , Transglutaminases/metabolism , Base Sequence , Calcium/metabolism , DNA Primers , Glycine/metabolism , Humans , Kinetics , Lipid Metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Solubility , Substrate Specificity , Transglutaminases/chemistry
18.
Mol Cell Biol ; 17(10): 6040-8, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9315663

ABSTRACT

The retinoblastoma gene product (pRB) plays an important role in controlling both cell release from the G1 phase and apoptosis. We show here that in the early phases of apoptosis, pRB is posttranslationally modified by a tissue transglutaminase (tTG)-catalyzed reaction. In fact, by employing a novel haptenized lysis synthetic substrate which allows the isolation of glutaminyl-tTG substrates in vivo, we identified pRB as a potential tTG substrate in U937 cells undergoing apoptosis. In keeping with this finding, we showed that apoptosis of U937 cells is characterized by the rapid disappearance of the 105,000- to 110,000-molecular-weight pRB forms concomitantly with the appearance of a smear of immunoreactive products with a molecular weight of greater than 250,000. The shift in pRB molecular weight was reproduced by adding exogenous purified tTG to extracts obtained from viable U937 cells and was prevented by dansylcadaverine, a potent enzyme inhibitor. The effect of the pRB posttranslational modification during apoptosis was investigated by determining the E2F-1 levels and by isolating and characterizing pRB-null clones from U937 cells. Notably, the lack of pRB in these U937-derived clones renders these p53-null cells highly resistant to apoptosis induced by serum withdrawal, calphostin C, and ceramide. Taken together, these data suggest that tTG, acting on the pRB protein, might play an important role in the cell progression through the death program.


Subject(s)
Apoptosis/physiology , Carrier Proteins , Cell Cycle Proteins , DNA-Binding Proteins , GTP Phosphohydrolases/metabolism , GTP-Binding Proteins , Monocytes/metabolism , Protein Processing, Post-Translational/physiology , Retinoblastoma Protein/metabolism , Transglutaminases/metabolism , Apoptosis/drug effects , Blood , Cadaverine/analogs & derivatives , Cadaverine/pharmacology , Cell Line , Ceramides/pharmacology , E2F Transcription Factors , E2F1 Transcription Factor , Enzyme Inhibitors/pharmacology , GTP Phosphohydrolases/antagonists & inhibitors , Humans , Monocytes/cytology , Mutation , Naphthalenes/pharmacology , Phosphorylation , Protein Glutamine gamma Glutamyltransferase 2 , Protein Kinase C/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/analysis , Retinoblastoma Protein/genetics , Retinoblastoma-Binding Protein 1 , Transcription Factor DP1 , Transcription Factors/analysis , Transglutaminases/antagonists & inhibitors , Tretinoin/pharmacology
19.
J Biol Chem ; 272(33): 20577-83, 1997 Aug 15.
Article in English | MEDLINE | ID: mdl-9252372

ABSTRACT

A lysine derivative, 3-[Nalpha[Nepsilon-[2', 4'-dinitrophenyl]-amino-n-hexanoyl-L-lysylamido]-propane-1-ol, a novel amine substrate of transglutaminases, was synthesized and delivered into intact HL-60 and U937 human leukemia cells to probe the function of the intracellular enzyme. The novel substrate compound was covalently incorporated into intracellular proteins in these cells expressing high levels of tissue transglutaminase and undergoing apoptosis following the induction of their differentiation with dimethyl sulfoxide and retinoic acid. Immunoaffinity purification and microsequencing of labeled proteins identified cytoplasmic actin as the main endogenous glutaminyl substrate in these cells. As shown by confocal image analysis, cells revealed distinct labeling of the microfilament meshwork structures by the novel compound as the result of the intracellular action of transglutaminase.


Subject(s)
Actins/metabolism , Apoptosis , Glutamine/metabolism , Transglutaminases/metabolism , Cytoplasm/metabolism , Dimethyl Sulfoxide/pharmacology , HL-60 Cells , Humans , Tretinoin/pharmacology
20.
FEBS Lett ; 404(2-3): 307-13, 1997 Mar 10.
Article in English | MEDLINE | ID: mdl-9119085

ABSTRACT

A significant increase in the expression and activity of tissue transglutaminase (tTG), one of the effector elements of apoptosis, was observed during involution of thymus elicited by treatment with either anti-CD3 antibody or dexamethasone or by irradiation. The blood plasma concentration of epsilon(gamma-glutamyl)lysine isodipeptide, the end-product of the digestion of transglutaminase cross-linked proteins, was also elevated in each of these cases. tTG was localized in cells of the cortical layer of the thymus and immunofluorescence double staining revealed that the enzyme appeared in the apoptotic cells. None of these observations could be made when apoptosis was induced by fas-receptor stimulation. The lack of tTG activity in fas-stimulated cells was accompanied with a less organized apoptotic morphology. Our data suggest that distinct signalling pathways, which induce apoptosis within the same cell type, can differentially regulate the expression of tTG, and this enzyme may be involved in structural stabilization of the apoptotic cells.


Subject(s)
Apoptosis , Gene Expression Regulation, Enzymologic , Signal Transduction , Thymus Gland/enzymology , Transglutaminases/biosynthesis , Animals , Antibodies, Monoclonal/pharmacology , Antigens, CD/immunology , Antigens, CD/physiology , Biomarkers , Dexamethasone/analogs & derivatives , Dexamethasone/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Kinetics , Male , Mice , Mice, Inbred Strains , Thymus Gland/cytology , Thymus Gland/physiology , Time Factors , Transglutaminases/analysis , fas Receptor/immunology , fas Receptor/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...